Skip to content
BY 4.0 license Open Access Published by De Gruyter April 3, 2023

Experience of patients with metastatic breast cancer in France: results of the 2021 RÉALITÉS survey and comparison with 2015 results

  • Jean-Sébastien Frenel EMAIL logo , Séverine Guiu , Laure Guéroult-Accolas , Nicole Zernik , Claudia Lefeuvre-Plesse and Isabelle Moley-Massol
From the journal Oncologie
An erratum for this article can be found here:



Metastatic breast cancer (MBC) and its treatments can significantly impact patient quality of life (QoL). In 2015, the RÉALITÉS 1 study documented the disease experience of 230 French patients. The objective of RÉALITÉS 2 was to analyse the evolution of QoL and the management of patients with MBC five years later.


Between September 2020 and February 2021, 266 patients with MBC completed a self-administered questionnaire on their understanding of their disease, its treatments and their impact on QoL.


Compared to 2015, patients had better knowledge of the metastatic status of their cancer (76 vs. 65%, p<0.01) and of treatment-related adverse events (81 vs. 71%, p<0.05). They felt that their oncologist listened to them more (78 vs. 68%, p<0.01) and were more likely to feel good when taking their treatment (73 vs. 60%, p<0.01). Although the use of certain supportive care increased, such as social assistance (36 vs. 26%, p<0.05) and aesthetic advice (26 vs. 16%, p<0.01), 44% of patients still did not make use of it. Anxiety (67% of patients in 2020–21) still has a major impact on the mental health of patients.


While many aspects of the QoL and management of patients with MBC have improved since 2015, there are still areas for improvement, such as access to supportive care and managing the impact of the psychological burden of the disease, for which different solutions may be considered.


In 2020, 2.26 million women were diagnosed with breast cancer, making it the most diagnosed cancer among women worldwide [1]. Through recent improvements in management, 70–80% of patients diagnosed at an early stage have an increased chance of recovery [2]. Unfortunately, in 20–30% of cases, cancer progresses to a metastatic stage [3]. Metastatic breast cancer (MBC) is a chronic disease that requires long-term treatment to slow its progression. Although supportive care is a major asset in reducing the side effects (physical and psychological) of MBC and its treatments [4], the latter can considerably impact patient quality of life and can represent a barrier to the implementation of patients’ personal and/or professional plans [5]. The incurable nature of MBC–combined with the unpredictable course of disease–increases patient vulnerability and strengthens their sense of inability to limit disease progression and improve their daily life [5, 6]. Patients’ knowledge of the disease and of care provision, as well as identification of the physical and psychological impact of MBC by healthcare professionals, are essential elements to help patients live better with their disease and facilitate implementation of a personalised care strategy [4, 7]. Unfortunately, there is little research on patient experience and solutions to improve quality of life [8, 9].

In this context, the RÉALITÉS study was set up in 2015 to identify different stages in the patient MBC treatment plan and analyse their experience with the disease, its treatments and their impact on daily lives [10]. The results of this first survey of 230 women with MBC showed an overall patient satisfaction with their care, but a significant negative impact of the disease on daily life and a need for additional information to patients [10]. Of the patients surveyed, only 65% were aware of the metastatic component of their cancer [10]. When the diagnosis of metastatic disease was shared, 60% of patients reported feeling supported and listened to, although half of them (49%) did not fully understand the information provided by the physician [10]. Generally, responding patients–and particularly those receiving chemotherapy–reported numerous adverse events (AEs) [10].

In recent years, the development of many therapies has improved patient prognosis and offered new perspectives [11]. CDK4/6 inhibitors are now recommended in combination with hormone therapy in patients with hormone-dependent MBC and HER2- (negative to the human epidermal growth factor receptor 2) at the metastatic stage [11], [12], [13], [14]. For patients with HER2+ MBC, first-line chemotherapy with trastuzumab and pertuzumab significantly improved survival. Other second-line HER2 inhibitors are available and have also had a considerable impact on patient outcomes [15]. In triple-negative MBC, first-line immunotherapy for PD-L1 positive tumours and PARP inhibitors for BRCA germ mutation, together with second-line sacituzumab-govitecan treatment, changed the management when only chemotherapy could be previously prescribed [16].

The RÉALITÉS 2 survey was set up with two objectives: highlight any evolution relating to patients’ understanding of their disease and to highlight satisfaction with the global management of their cancer since the first RÉALITÉS study in 2015; via a mirror survey with the patient’s oncologist to better assess knowledge of their disease and treatments implemented. This article analyses “patient” data collected in 2020–2021 and compares them with those of 2015 when possible. Mirror physician/patient data collected via this survey will be published at a later date.


RÉALITÉS 2 was a national survey conducted from 21 September 2020 to 8 February 2021 among French oncologists and patients. Patients were recruited through their oncologists who had previously agreed to participate in the survey. To be included in the survey, oncologists had to be actively treating at least 10 patients with MBC. Five hundred and three doctors treating patients with breast cancer were contacted by telephone or email. Seventy of them met the inclusion criteria and were informed about the objectives of this survey and how to participate in it, and 57 physicians agreed to take part and to include up to six volunteer patients each. Patients were sought for the survey based on a diagnosis of MBC, with no other specific selection criteria. Each patient included in the survey was asked by their physician to complete a paper-based self-administered questionnaire that took around 30 min to complete (Supplementry Figure 1). Developed by a multidisciplinary scientific committee, it consisted of 36 questions covering sociodemographic data (age, place of residence, profession), disease monitoring (healthcare professionals consulted, type of healthcare facility), knowledge of the disease (metastatic component, tumour status), diagnosis of the metastatic disease, treatments and their impact, particularly in terms of adverse events (AEs), supportive care, global perception of disease, information sought by patients and suggestions for improving disease management. A descriptive statistical analysis of these data was conducted. Quantitative variables were expressed as means and standard deviations (SD), medians and intervals, and qualitative variables were expressed as numbers of individuals and percentages. To assess the impact of certain criteria on responses, such as the type of centre where surveyed patients were treated, sub-populations were compared using the Student’s t-test for averages and the Chi-square test for percentages on the 2020–2021 data. The significance threshold was defined for a p value <0.05.


Profile of responding patients

Two hundred and sixty-six patients and 57 physicians responded to the RÉALITÉS 2 survey conducted in 2020–2021 while 230 and 48 respectively had participated in the 2015 RÉALITÉS 1 survey. The characteristics of participating patients are described in Table 1. Patients in the RÉALITÉS 2 survey were on average 62.3 years old (vs. 59.2 years in 2015, p<0.01). More than half were retired (56 vs. 48% in 2015, p<0.1), one-third were on sick leave/occupational disability (31 vs. 34% in 2015, NS) and 12% (vs. 15% in 2015, NS) were employed. Compared to 2015, more of these patients had children (85 vs. 75%, p<0.01) or belonged to a patient association (8 vs. 0%, p<0.01).

Table 1:

Profile of patients participating in the survey.

RÉALITÉS 2 (2021) (n=266) RÉALITÉS 1 (2015) (n=230)
Average age, years 62.3 59.2 p<0.01
Family status, %

With a partner 54 53 NS
Alone 24 27 NS
With family 22 17 NS
At home 0 0 NS
In a retirement home 0 1 NS
NR 0 2 NS
With children, % 85 75 p<0.01

Employment status, %

Retired/not active 56 48 p<0.1
On sick leave/disability 30 34 NS
Employed 12 15 NS
NR 2 3 NS

Distance from hospital to home, %

<30 min travel time 48 47 NS
>30 min and <1 h travel time 34 34 NS
About 1 h travel time 10 13 NS
>1 h and <2 h travel time 5 5 NS
>2 h travel time 0 1 NS
NR 3 0 NS

Current or former occupation, %

Self-employed farmer or fisherman 2 7 NS
Craftsman, merchant, business owner 10 8 NS
Manager, executive/freelance 8 12 NS
Intermediate profession/teacher 14 12 NS
Employee 45 36 NS
Labourer 9 7 NS
Not working 9 12 NS
NR 3 6 NS
Member of a patient association, % 8 0 p<0.01
Patients mentioning the metastatic stage, % 76 65 p<0.01

Patient-reported tumour status, %

HR + HER2- 19 20 NS
HR + HER2+ 7 8 NS
HR-HER2- 8 7 NS
HR-HER2+ 3 4 NS
Do not know, other, NR 63 61 NS

Physician-reported centre of care, %

University/regional hospital centre 21 NA NA
Hospital centre 39 NA NA
Cancer centre 21 NA NA
Private clinic 19 NA NA
  1. HER2, human epidermal growth factor receptor 2; NA, not applicable; NR, no response; NS, not significant; HR, hormone receptor.

Patients interviewed in 2020–2021 showed better knowledge of the metastatic stage (76 vs. 65%, p<0.01) and identical knowledge of their tumour status (hormone dependent, HER2 overexpression, triple negative) vs. 2015 (37 vs. 39%, NS; Table 1).

Current or past treatments

Compared to the first survey, patients experienced more pre-treatment, including hormonal therapy, targeted therapy, radiation therapy sessions, or previous/current surgery (Table 2).

Table 2:

Current and past treatments of responding patients.

RÉALITÉS 2 (2021) (n=266) RÉALITÉS 1 (2015) (n=230)
Current and prior treatments, %

Chemotherapy 72 67 NS
Hormone therapy 60 41 p<0.01
Targeted therapy 43 24 p<0.01
Radiotherapy 53 19 p<0.01
Surgery 45 8 p<0.01
Other/do not know 7 1 p<0.01

Current treatment, %

Injectable treatment 54 62 p<0.05
Multiple drugs per day 45 55 p<0.05
  1. NS, not significant.

At the time of the survey, 99% of respondents received at least one treatment for their MBC (vs. 97% in 2015, NS). Compared to 2015, significantly more patients felt well when on their treatment in 2020–2021 (73 vs. 60%, p<0.01), did not find it at all restrictive (21 vs. 11%, p<0.01) or did not want to stop it at all (38 vs. 24%, p<0.01). These global data masked sensitive differences depending on the nature of the treatment received; chemotherapy was associated with a significantly more negative perception (Figure 1).

Figure 1: 
Perception of current treatment.
Figure 1:

Perception of current treatment.

The same applied to AEs, affecting 82% of responders on chemotherapy (vs. 77% in 2015, NS), 61% of those on hormone therapy (vs. 50% in 2015, NS) and 66% of those on targeted therapy (vs. 50% in 2015, NS).

In all treatments combined, fatigue remained the most reported AE (82% of patients in 2015 and 2020–2021), particularly in patients coming from a university/regional hospital centre (94.7%, p<0.001), followed by nausea, hair loss, pain and skin dryness for 48, 46, 43 and 41% of 2020–2021 responders, respectively (Figure 2). As in 2015, patients reported a significant negative impact of these AEs on their daily lives (Figure 2).

Figure 2: 
Adverse events (AE) experienced and impact on patient daily lives.
Figure 2:

Adverse events (AE) experienced and impact on patient daily lives.

Regarding information received on treatment, 74% of patients were able to ask their doctor their questions, 74% felt well supported and 81% said they were informed about AEs of treatments; percentages were significantly higher than in 2015 (Table 3).

Table 3:

Information received about current treatment.

RÉALITÉS 2 (2021) (n=266) RÉALITÉS 1 (2015) (n=230)
I feel well informed about this treatment 83% 79% NS
The doctor has informed me of any possible adverse event(s) experienced with this treatment 81% 71% p<0.05
I was able to ask any questions I wanted about this treatment 74% 66% p<0.05
Regarding this treatment, I felt well supported 74% 66% p<0.1
  1. NS, not significant.

Metastatic disease announcement consultation

Globally, the time dedicated to the announcement of metastatic disease was considered sufficient by 83% of patients surveyed in 2020–2021; the percentage increased compared to 2015 (77%, p<0.1). Patient perception of this announcement also improved in 2020–2021 compared to 2015: a total of 78% felt their doctor had taken the time to listen to them (vs. 68% in 2015, p<0.05); 73% were able to ask their questions (vs. 58% in 2015, p<0.01), 74% felt well supported (vs. 63% in 2015, p<0.01) and 62% understood the information provided by the doctor (vs. 51% in 2015, p<0.05) (Table 4). However, results from 2020 to 2021 subgroup analyses showed disparities depending on the type of hospital: fewer cancer centre (Centre de Lutte Contre le Cancer–CLCC) patients felt listened to (67.3%, p<0.05) while more patients treated in private clinics felt able to ask their questions (84%, p<0.05).

Table 4:

Perception and understanding of the announcement of metastatic disease.

RÉALITÉS 2 (2021) (n=266) RÉALITÉS 1 (2015) (n=230)
Sufficient time was given to announce metastases 83% 77% p<0.1
The doctor took the time to explain 82% 81% NS
The doctor took the time to listen to me 78% 68% p<0.05
I was able to ask the questions I wanted 73% 58% p<0.01
I felt well supported 74% 63% p<0.01
The doctor gave me the information I wanted 69% 63% NS
I have understood the information provided by the doctor 62% 51% p<0.05
  1. NS, not significant.

As in 2015, half of patients surveyed reported having received a disease information leaflet (54 vs. 47% in 2015, NS) and one quarter received the contact details of a patient association (28 vs. 19% in 2015, NS) (Supplementary Table 1). In addition, more patients from hospital centres (62.5%, p<0.05) reported having received a disease information leaflet, and more patients from a private clinic (44%, p<0.001) received contact details of a patient association. Overall, fewer patients sought information from their healthcare professionals following the announcement of metastatic disease: 46% consulted their general practitioner (GP) in 2020–2021 (vs. 58% in 2015, p<0.01), 30% contacted their oncologist (vs. 53% in 2015, p=0.01) and 14% consulted a psychologist (vs. 27% in 2015, p<0.01; Supplementary Table 2).

Supportive care

Except for the psychologist, who was consulted less in 2020–2021 than in 2015 (36 vs. 47%, p<0.05), and even less in CLCC (18.2%, p<0.001), patients consulted more frequently a social worker (36 vs. 26% in 2015, p<0.05), an aesthetic consultant (26 vs. 16% in 2015, p<0.01) and a physical activity facilitator (18 vs. 13% in 2015, p<0.1) (Figure 3). These results were even higher for patients in hospital centres and private clinics, who more frequently consulted a social worker (45.2%, p<0.05) and a physical activity facilitator (30%, p<0.05), respectively. These resources were deemed useful by 88% of patients (vs. 69% in 2015, p<0.05). The main reasons cited in 2020–2021 by the 46% of patients who did not receive supportive care were the absence of proposals by healthcare professionals (40% of cases), particularly in university/regional hospital centres (75% of cases, p<0.001), and the lack of desire to receive this type of care (41%), especially by patients from hospital centres (53.7%, p<0.05).

Figure 3: 
Supportive care provided.
Figure 3:

Supportive care provided.

Non-reimbursable expenses

While fewer patients surveyed in 2020–2021 reported non-reimbursable expenses for their MBC (29 vs. 43% in 2015, p<0.01), the subpopulation analysis showed that patients who received supportive care reported significantly more non-reimbursable expenses than those who did not: 39 vs. 19% (p<0.01).

Living with the disease

Compared to 2015, several aspects of patient experience with their MBC changed positively: patients felt more informed (86 vs. 80% in 2015, p<0.1), spoke more to their friends and family (71 vs. 57% in 2015, p<0.01) and had less difficulty complying with their treatment (24 vs. 31% in 2015, p<0.1; Table 5). Other aspects, however, did not change since 2015 and showed a reduced quality of life in a large majority of patients with significant mental burden: such as thinking about the disease every day, anxiety during follow-up visits and obstacles to fulfilling their future plans (Table 5).

Table 5:

Living with the disease.

RÉALITÉS 2 (2021) (n=266) RÉALITÉS 1 (2015) (n=230)
I feel well informed about the disease 86% 80% p<0.1
I am lucky to be well supported (family, friends); it helps me fight the disease 84% 80% NS
It’s a disease I think about every day 72% 71% NS
I can easily talk about this disease with friends and family 71% 57% p<0.01
I am always anxious before going to the hospital to see the doctor or do tests 67% 72% NS
It’s a disease that never leaves me alone 64% 67% NS
The disease prevents me from carrying out my plans and from thinking about the future 64% 69% NS
I easily discuss this disease with other patients (in the hospital, for example) 54% 52% NS
I find it difficult to meet my professional obligations as before 26% 42% NS
I find it difficult to comply with my treatments properly; I often want to stop taking them 24% 31% p<0.1
  1. NS, not significant.


In 2015, the RÉALITÉS 1 survey, the first large-scale study carried out in France on the experience of women with MBC, showed overall satisfaction of patients regarding their care and the support provided by the medical profession. In contrast, areas for improvement emerged regarding understanding information received, and the significant negative impact of the disease on daily life. In 2020–2021, the objective of the RÉALITÉS 2 survey was to measure any evolution in perception in patients with MBC regarding their disease and management.

According to our study, management of MBC has changed positively in several aspects over the last five years. Patients who are better informed about their treatment are more likely to feel good when taking their treatment and not want to stop it. When it comes to announcing a metastatic disease, more people felt listened to and understood the information provided by their oncologist. Data collected from analyses of internet forums provide a less optimistic insight into this. An analysis of the French breast cancer platform “Les Impatientes” showed that patients frequently regretted having a lack of information and insufficient dialogue with healthcare professionals due to an incomplete understanding of their treatment plan [17]. Similarly, the 2013 pan-European patient survey in 216 responders showed that 51% of patients with locally advanced or MBC felt that their care would be improved if healthcare professionals listened more [18]. In a national sub-analysis of the large European study on social networks and MBC conducted between 2018 and 2020 in 14 European countries, Mazza et al. described that the needs most frequently expressed in the 8,410 French conversations analysed were unavailability of effective treatment, lack of effective screening and lack of empathy from certain healthcare professionals [19]. Conversely, a general review of the literature conducted in 2019 showed that most patients with MBC were satisfied with the emotional, psychosocial, informational and medical support received from relatives and healthcare professionals [20]. From a psychological point of view, the occurrence of MBC leads to an emotional charge that is at least equal to that of the initial diagnosis, with additional specific constraints: feeling that things could have been done differently to avoid a relapse, having to tell people about the disease again, uncertainty about the efficacy of treatments and fear of the spread of the disease in the body [21]. In addition, there may be a feeling of isolation, and a lack of understanding by society in general and the community of patients with localised breast cancer, in particular [21, 22]. Far from being contradictory, these perception differences illustrate the diversity of patient feelings towards the medical profession at this stage of the disease, ranging from recognition of the quality of information provided and the new treatment plan proposed, to the difficulty generated by the lack of a therapeutic solution that makes it possible to consider, as in the initial stage, a cure.

In our 2020–2021 RÉALITÉS survey, evolution of supportive care was mixed. Consulting social workers, seeking aesthetic advice, and especially physical activity increased compared to 2015. However, almost half of patients still did not receive any complementary care, with 18% receiving no proposal of supportive care. In another survey conducted in Singapore in 411 patients with colorectal, breast or lung cancer, the satisfaction level relating to supportive care was low, despite being rated as important information [23]. In addition, the financial burden of non-reimbursed costs, which decreased in the overall sample, increased particularly in patients receiving this additional care. A prospective study carried out in France in 2018 on patients starting a new treatment for their MBC also showed an unequal use of supportive care: pain consultation = 43% of patients (24% in our 2020 survey); consultation with a psychologist = 37% (36% in our survey); physiotherapist = 30% (33% in our survey); social assistance = 22% (36% in our survey); aesthetic care = 18% (26% in our survey) and nutritional care = 18% (36% in our survey) [24]. In a recent literature review on supportive care in MBC, the authors pointed out that one key to optimal patient care is the management by an oncologist also trained in supportive care [25]. This is the notion of comprehensive care with the Anglo-Saxon concept of cure and care.

In our survey, 36% of patients surveyed in 2020–2021 reported receiving advice about or a prescription for physical activity from their oncologist. This illustrates the increasing place of this complementary treatment in the therapeutic arsenal. Recent data demonstrating the effectiveness of physical activity in reducing fatigue, and in improving quality of life, psychological and emotional state of cancer patients and treatment compliance are numerous [26], [27], [28], [29], [30], [31], [32], [33]. The causes of under-use of supportive care, which is still too infrequent in MBC, are also better studied and include limitation of evidence on the feasibility and effectiveness of this advanced-stage care, and lack of knowledge of healthcare professionals and patients regarding the safety and benefits of such a practice [29, 32]. In terms of modalities, one-third of patients indicated a preference for group exercise under professional supervision, ideally with patients who also have metastatic cancer [34].

Our survey shows that some aspects of the experience of MBC have not progressed favourably between 2015 and 2020–2021. Treatment AEs, particularly chemotherapy, are still strongly felt daily. It should be noted that the results of the oncologist-patient mirror survey (not presented here) show a lack of patient knowledge of their treatments, which may lead to bias in the declaration of tolerance. This lack of knowledge could be related to patients’ willingness to be informed. Indeed, a survey conducted in Italy in 2008 in 587 patients with breast, gastrointestinal or other forms of cancer showed that only 57% of cancer patients were keen to receive information regarding their treatment opportunities [35]. However, when looking at the European scale, the pan-European 2013 survey showed that 68% of patients with locally advanced or MBC wanted more information about future medical treatments and research [23]. At the metastatic stage, most women present treatment-related AEs, impaired quality of life, pain, fatigue or insomnia-related discomfort, sometimes associated with menopausal symptoms [19, 21]. Emotionally, episodes of depression and anxiety are common [21]. Often, these AEs are accepted with resignation, as a price to pay for the benefit of treatment and for which nothing can be done [36]. A French study showed that the diagnosis of cancer induces a significant reduction or even discontinuation of all activity in a majority of patients who were physically active before their diagnosis [30]. In a survey of 114 women with MBC for an average of 4.3 years and treated with chemotherapy (24%), hormone therapy (56%) or targeted therapy (14%), 86% of women reported at least one problem limiting their physical activity: difficulty running (58%), standing for an extended period of time (55%), exercising (33%) or performing domestic activities (32%) [34]. The main barriers reported were fatigue (54%), arthralgia or myalgia (42 and 29%), and dyspnoea (25%) [34].

As in 2015, fatigue was the most frequently reported AE in our 2020–2021 RÉALITÉS survey (82% of patients), ahead of nausea (48%), alopecia (46%), pain (43%) and skin dryness (41%). In a 2016 meta-analysis involving more than 12,000 patients treated for breast cancer, reported rates of severe fatigue were between 7 and 52% with a median of 27% [37]. This rate seems to increase significantly in patients treated with chemotherapy. In a study of 67 patients treated for breast cancer between November 2017 and June 2019, clinically significant fatigue was reported in 46%, with two significant worsening factors: high number of treatments and presence of bone metastases [38]. This fatigue may persist beyond treatment, as shown by a recent Dutch study which compared 350 patients treated for breast cancer occurring at least five years prior with an equivalent sample in terms of age and consulting a GP, but without a history of cancer: after a median follow-up of 10 years, 27% of women still experienced persistent general physical and psychological fatigue, which is a significantly higher rate than women without a history of cancer [39].

Despite recent improvements in antiemetic administration, chemotherapy-induced nausea and vomiting (CINV) are still considered a major AE in cancer treatments [40], [41], [42]. In a recent retrospective study, 78% of the 98 breast cancer patients treated with chemotherapy still reported CINV despite receiving specific treatment, and more than two-thirds blamed these AEs for the significant impact on their quality of life [40].

The prevalence and pain management of metastatic cancer were studied in a French study conducted in 233 patients (72% of whom had breast cancer) seen in an outpatient clinic appointment in 2013 and 2014, outside the framework of the MBC announcement [43]. Fifty-five per cent of MBC patients were algetic, 38% of whom had been in pain for at least three months; in 6 out of 10 cases, background pain was associated with pain attacks. Pain was managed in 83% of cases by the oncologist, in 68% of cases by the GP and in 16.5% of cases by a doctor specialised in pain or supportive care. The impact of pain on patient life was major: 79% reduction in usual domestic activities, 72% induced fatigue, 67% limitation of outdoor activities or movement, 55% reduction in sleep and 54% mood alteration [43]. In a Brazilian trial of 400 breast cancer patients, pain was reported in 86% of those with metastatic disease (122 MBC in the trial) with a direct negative impact on quality of life (assessed by the EORTC QLQ-C30 questionnaire) and functional capabilities [44]. Finally, in a 2018 French prospective study of 78 patients with MBC, three factors contributed significantly to improving their health: treatment as initially planned, disease control and adequate pain control [24].

Cutaneous and mucosal side effects have recently been studied in patients with breast cancer. In the adjuvant setting, 24% of the 190 patients treated with chemotherapy had dermatological AEs after a median of 4.5 cycles; lesions developed for 6.2 days and improved only after an average of 25 days (vs. 6.2 days for mucositis) [45]. In another cohort, 250 patients, i.e. 35% of the 720 patients followed up in 2019 and 2020, presented at least one cutaneous AE; 86% of them were treated with chemotherapy and 14% with targeted therapy [46]. The impact of these AEs on body image and quality of life is widely documented [47, 48].

The RÉALITÉS 2020–2021 survey showed that the psychological burden of MBC remains considerable in terms of anxiety and obstacles to carrying out plans. In another international study called BRIDGE in 1,342 women with MBC, despite the fact that 59% of women with MBC coped with an array of daily negative emotions and concerns, 74% of them were still able to enjoy life [49]. At the time of diagnosis (localised tumour), the perception of metastases is closely associated with death. The announcement of metastatic disease implies a change in the perception of the disease which must now be considered as a chronic disease of limited duration [21]. Women with MBC often experience decreased self-esteem and fears for the future [36]. All these factors promote neither the expression of future plans nor attainment of personal goals that are strongly disrupted by the experience of cancer and associated symptoms [50], [51], [52]. Sexual difficulties are frequently reported and there is regret over the lack of dialogue and support from healthcare professionals on this [20, 36].

The results of subgroup analyses conducted in RÉALITÉS 2020–2021 suggest that there is a gap between public and private sectors in terms of the information given to patients and the amount of time and type of care that patients can access. However, as the study was not designed to evaluate differences in care management based on the type of care centre, further studies could help to establish the reasons behind the discrepancies found in this survey.

The main limitation of this comparison between the two waves of the RÉALITÉS survey was patient recruitment, selected by a limited number of oncologists: 48 in 2015 and 57 in 2020–2021 out of a total of 1,675 French medical oncologists and radiotherapists [53]. Another limitation was that the characteristics of respondents were not superimposed. Compared to 2015, 2020–2021 patients were a little older (62 vs. 59 years old) and had experienced stronger pre-treatment. This greater “breakthrough” in the disease can change the perception of cancer management and constraints, and reduce the value of our comparison. The arrival of new significant therapeutic options between 2015 and 2020 has modified disease management in some MBC patients (particularly those with an HR + HER2- and TN tumour) and the perception of their management. Finally, although validated questionnaires to assess quality of life in cancer patients exist, they were not used in this study. Indeed, the objective of the RÉALITÉS studies was not to provide a quality of life assessment tool but to gather information about the experience and satisfaction with their cancer management of women with MBC. Therefore, we specifically developed the questionnaires used in the RÉALITÉS 1 and 2 to meet this objective and to be easily completed by patients alone.

Nevertheless, the large size of our sample, its homogeneity (only MBC) and, above all, repetition of the same study methodology five years after the first wave, allowed a comparative analysis that, to our knowledge, is unprecedented.


Between 2015 and 2020–2021, the RÉALITÉS survey has shown that important aspects of the management of patients with MBC has progressed, including the quality of information received and interactions with the oncologist. However, there are still important areas for improvement: access to supportive care, reduction and management of AEs, and the psychological impact of a relapse. Different solutions are possible, such as training oncologists in supportive care and improving information materials given to patients to improve knowledge of the disease and its treatments. A greater transfer of follow-up tasks to advanced practice nurses, GPs, community nurses, community pharmacists and the involvement of patient associations throughout the treatment plan would promote improved access to care and more comprehensive cancer management.

Corresponding author: Dr. Jean-Sébastien Frenel, Department of Medical Oncology, Institut de Cancérologie de l’Ouest, Bd Jacques Monod, 44805 Saint-Herblain, France, E-mail:
This work is licensed under a Creative Commons Attribution 4.0 International License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


The authors thank Pfizer for its financial support in completing the study, and A+A for operational completion. The Pfizer laboratory had no role in interpreting and discussing the data, or in preparing this manuscript.

  1. Author contributions: All authors developed the concept and methodology of this study, including the design of the questionnaire, under the supervision of (I.MM). Data analysis and drafting of the original version were carried out by (JS.F and I.MM). (S.G, L.GA, N.Z and C.LP) have reviewed, edited and approved the manuscript.

  2. Conflicts of interest: JS.F declares having received consulting fees for AstraZeneca, Daiichi-Sankyo, Clovis Oncology, Exact Science, Gilead, GSK, Lilly, MSD, Novartis, Pfizer, and Seagen, payment or honoraria for lectures, presentations speakers bureaus, manuscript writing or educational events for AstraZeneca, Daiichi-Sankyo, Gilead, Lilly, MSD, Novartis, and Seagen, and support for attending meetings and/or travel for AstraZeneca, Daiichi-Sankyo, Clovis Oncology, Gilead, GSK, Lilly, MSD, Novartis, Pfizer, and Seagen. L.GA declares having received advisory/consultancy fees for AstraZeneca, Daiichi-Sankyo, Lilly, Novartis, Pfizer, Roche, Seagen, and Vifor, and travel/accommodation/expenses fees for Exact Sciences, Pfizer, Seagen, and Vifor. The remaining authors declare that they have no conflicts of interest to report regarding the present study.

  3. Ethical considerations: Ethical considerations and data privacy have been respected. Prior authorisation has been obtained from the various hospital managers.

  4. Data availability: The data are available in the hospital’s collection database and medical documents are accessible in compliance with ethics and confidentiality.


1. Ferlay, J, Colombet, M, Soerjomataram, I, Parkin, DM, Piñeros, M, Znaor, A, et al.. Cancer statistics for the year 2020: an overview. Int J Cancer 2021;149:778–89. in Google Scholar PubMed

2. Harbeck, N, Penault-Llorca, F, Cortes, J, Gnant, M, Houssami, N, Poortmans, P, et al.. Breast cancer. Nat Rev Dis Prim 2019;5:1–31. in Google Scholar PubMed

3. Chen, W, Hoffmann, AD, Liu, H, Liu, X. Organotropism: new insights into molecular mechanisms of breast cancer metastasis. npj Precision Onc 2018;2:1–12. in Google Scholar PubMed PubMed Central

4. Zdenkowski, N, Tesson, S, Lombard, J, Lovell, M, Hayes, S, Francis, PA, et al.. Supportive care of women with breast cancer: key concerns and practical solutions. Med J Aust 2016;205:471–5. in Google Scholar PubMed

5. Müller, V, Nabieva, N, Häberle, L, Taran, FA, Hartkopf, AD, Volz, B, et al.. Impact of disease progression on health-related quality of life in patients with metastatic breast cancer in the PRAEGNANT breast cancer registry. Breast 2018;37:154–60. in Google Scholar PubMed

6. Johnston, SRD. Living with secondary breast cancer: coping with an uncertain future with unmet needs: guest editorial. Eur J Cancer Care 2010;19:561–3. in Google Scholar PubMed

7. Tian, J, Jia, LN, Cheng, ZC. Relationships between patient knowledge and the severity of side effects, daily nutrient intake, psychological status, and performance status in lung cancer patients. Curr Oncol 2015;22:254–8. in Google Scholar PubMed PubMed Central

8. Willis, K, Lewis, S, Ng, F, Wilson, L. The experience of living with metastatic breast cancer—a review of the literature. Health Care Women Int 2015;36:514–42. in Google Scholar PubMed

9. Institut national du cancer. Étude sur l’annonce du diagnostic de cancer et le ressenti des malades en 2011; 2012. Available from: in Google Scholar

10. Espié, M, Moley-Massol, I, Zernik, N, Debiais, D, Diéras, V. Metastatic breast cancer: patient journey, patient needs, and expectations: results of the RÉALITÉS national survey. Oncol 2018;20:73–83. in Google Scholar

11. Manohar, PM, Davidson, NE. Updates in endocrine therapy for metastatic breast cancer. Cancer Biol Med 2021;19:202–12. in Google Scholar PubMed PubMed Central

12. Serra, F, Lapidari, P, Quaquarini, E, Tagliaferri, B, Sottotetti, F, Palumbo, R. Palbociclib in metastatic breast cancer: current evidence and real-life data. DIC 2019;8:1–16. in Google Scholar PubMed PubMed Central

13. Corona, SP, Generali, D. Abemaciclib: a CDK4/6 inhibitor for the treatment of HR+/HER2– advanced breast cancer. DDDT 2018;12:321–30.10.2147/DDDT.S137783Search in Google Scholar PubMed PubMed Central

14. Hortobagyi, GN, Stemmer, SM, Burris, HA, Yap, YS, Sonke, GS, Paluch-Shimon, S, et al.. Ribociclib as first-line therapy for HR-positive, advanced breast cancer. N Engl J Med 2016;375:1738–48. in Google Scholar PubMed

15. Martínez-Sáez, O, Prat, A. Current and future management of HER2-positive metastatic breast cancer. JCO Oncol Pract 2021;17:594–604. in Google Scholar PubMed

16. Gennari, A, André, F, Barrios, CH, Cortés, J, de Azambuja, E, DeMichele, A, et al.. ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer. Ann Oncol 2021;32:1475–95. in Google Scholar PubMed

17. Cherif, E, Martin-Verdier, E, Rochette, C. Investigating the healthcare pathway through patients’ experience and profiles: implications for breast cancer healthcare providers. BMC Health Serv Res 2020;20:1–11. in Google Scholar PubMed PubMed Central

18. Harding, V, Afshar, M, Krell, J, Ramaswami, R, Twelves, CJ, Stebbing, J. ’Being there’ for women with metastatic breast cancer: a pan-European patient survey. Br J Cancer 2013;109:1543–8. in Google Scholar PubMed PubMed Central

19. Mazza, M, Piperis, M, Aasaithambi, S, Chauhan, J, Sagkriotis, A, Vieira, C. Social media listening to understand the lived experience of individuals in europe with metastatic breast cancer: a systematic search and content analysis study. Front Oncol 2022;12:1–13. in Google Scholar PubMed PubMed Central

20. Bochenek-Cibor, J, Górecka, M, Storman, D, Bała, MM. Support for metastatic breast cancer patients—a systematic review. J Cancer Educ 2020;35:1061–7. in Google Scholar PubMed PubMed Central

21. Ciria-Suarez, L, Jiménez-Fonseca, P, Palacín-Lois, M, Antoñanzas-Basa, M, Fernández-Montes, A, Manzano-Fernández, A, et al.. Breast cancer patient experiences through a journey map: a qualitative study. PLoS One 2021;16:1–23. in Google Scholar PubMed PubMed Central

22. Cardoso, F, Harbeck, N, Mertz, S, Fenech, D. Evolving psychosocial, emotional, functional, and support needs of women with advanced breast cancer: results from the Count Us, Know Us, Join Us and Here & Now surveys. Breast 2016;28:5–12. in Google Scholar PubMed

23. Chua, GP, Tan, HK, Gandhi, M. What information do cancer patients want and how well are their needs being met? Ecancermedicalscience 2018;12:1–16. in Google Scholar PubMed PubMed Central

24. Arnaud, A, Grenier, J, Boustany, R, Kirscher, S, Mege, A, de Rauglaudre, G, et al.. Role of supportive care in improving the quality of life and reducing unscheduled hospital care in patients with metastatic breast cancer. Support Care Cancer 2021;29:3735–42. in Google Scholar PubMed

25. Kida, K, Olver, I, Yennu, S, Tripathy, D, Ueno, NT. Optimal supportive care for patients with metastatic breast cancer according to their disease progression phase. JCO Oncol Pract 2021;17:177–83. in Google Scholar

26. Buffart, LM, Kalter, J, Sweegers, MG, Courneya, KS, Newton, RU, Aaronson, NK, et al.. Effects and moderators of exercise on quality of life and physical function in patients with cancer: an individual patient data meta-analysis of 34 RCTs. Cancer Treat Rev 2017;52:91–104. in Google Scholar PubMed

27. Kim, JY, Lee, MK, Lee, DH, Kang, DW, Min, JH, Lee, JW, et al.. Effects of a 12-week home-based exercise program on quality of life, psychological health, and the level of physical activity in colorectal cancer survivors: a randomized controlled trial. Support Care Cancer 2019;27:2933–40. in Google Scholar PubMed

28. Kessels, E, Husson, O, Van der Feltz-Cornelis, CM. The effect of exercise on cancer-related fatigue in cancer survivors: a systematic review and meta-analysis. NDT 2018;14:479–94. in Google Scholar

29. Heywood, R, McCarthy, AL, Skinner, TL. Safety and feasibility of exercise interventions in patients with advanced cancer: a systematic review. Support Care Cancer 2017;25:3031–50. in Google Scholar PubMed

30. Matias, M, Baciarello, G, Neji, M, Di Meglio, A, Michiels, S, Partridge, AH, et al.. Fatigue and physical activity in cancer survivors: a cross-sectional population-based study. Cancer Med 2019;8:2535–44. in Google Scholar PubMed PubMed Central

31. Mustian, KM, Alfano, CM, Heckler, C, Kleckner, AS, Kleckner, IR, Leach, CR, et al.. Comparison of pharmaceutical, psychological, and exercise treatments for cancer-related fatigue: a meta-analysis. JAMA Oncol 2017;3:961–8. in Google Scholar PubMed PubMed Central

32. Salakari, MRJ, Surakka, T, Nurminen, R, Pylkkänen, L. Effects of rehabilitation among patients with advances cancer: a systematic review. Acta Oncol 2015;54:618–28. in Google Scholar PubMed

33. Neuzillet, C, Bouché, O, Tournigand, C, Chibaudel, B, Bouguion, L, Bengrine-Lefevre, L, et al.. Adapted physical activity in patients (Pts) with advanced pancreatic cancer (APACaP): results from a prospective national randomized GERCOR trial. J Clin Orthod 2022;40:4007. in Google Scholar

34. ten Tusscher, MR, Groen, WG, Geleijn, E, Sonke, GS, Konings, IR, Van der Vorst, MJ, et al.. Physical problems, functional limitations, and preferences for physical therapist-guided exercise programs among Dutch patients with metastatic breast cancer: a mixed methods study. Support Care Cancer 2019;27:3061–70. in Google Scholar PubMed

35. Bracci, R, Zanon, E, Cellerino, R, Gesuita, R, Puglisi, F, Aprile, G, et al.. Information to cancer patients: a questionnaire survey in three different geographical areas in Italy. Support Care Cancer 2008;16:869–77. in Google Scholar PubMed

36. Laporte, C, Vaure, J, Bottet, A, Eschalier, B, Raineau, C, Pezet, D, et al.. French women’s representations and experiences of the post-treatment management of breast cancer and their perception of the general practitioner’s role in follow-up care: a qualitative study. Health Expect 2017;20:788–96. in Google Scholar PubMed PubMed Central

37. Abrahams, HJ, Gielissen, MF, Schmits, IC, Verhagen, CA, Rovers, MM, Knoop, H. Risk factors, prevalence, and course of severe fatigue after breast cancer treatment: a meta-analysis involving 12 327 breast cancer survivors. Ann Oncol 2016;27:965–74. in Google Scholar PubMed

38. Hajj, A, Chamoun, R, Salameh, P, Khoury, R, Hachem, R, Sacre, H, et al.. Fatigue in breast cancer patients on chemotherapy: a cross-sectional study exploring clinical, biological, and genetic factors. BMC Cancer 2022;22:1–11. in Google Scholar PubMed PubMed Central

39. Maass, SW, Brandenbarg, D, Boerman, LM, Verhaak, PF, de Bock, GH, Berendsen, AJ. Fatigue among long-term breast cancer survivors: a controlled cross-sectional study. Cancers 2021;13:1–11. in Google Scholar

40. Ilyas, AB, Bahaj, RK, Shaikh, AA, Khawandanah, BS, Al-Foheidi, M, Omer, TY. Breast cancer patients’ perceptions of their experience with chemotherapy-induced nausea and vomiting and its impact on quality of life in jeddah, Saudi arabia. Cureus 2020;12:1–9. in Google Scholar PubMed PubMed Central

41. Al Qadire, M. Chemotherapy-induced nausea and vomiting: incidence and management in Jordan. Clin Nurs Res 2018;27:730–42. in Google Scholar PubMed

42. Lua, PL, Salihah Zakaria, N, Mazlan, N. Chemotherapy-induced nausea and vomiting: exploring patients’ subjective experience. JMDH 2016;9:145–51.10.2147/JMDH.S97695Search in Google Scholar PubMed PubMed Central

43. Dénommé, F, Kroemer, M, Montcuquet, P, Nallet, G, Thiery-Vuillemin, A, Bazan, F, et al.. Prévalence et prise en charge de la douleur chez les patients présentant un cancer métastatique en Franche-Comté. Bull Cancer 2016;103:849–60. in Google Scholar PubMed

44. Costa, WA, Monteiro, MN, Queiroz, JF, Gonçalves, AK. Pain and quality of life in breast cancer patients. Clinics 2017;72:758–63. in Google Scholar PubMed PubMed Central

45. Alizadeh, N, Mirpour, SH, Darjani, A, Rafiei, R, Rafiei, E, Mohammadhoseini, M. Dermatologic adverse effects of breast cancer chemotherapy: a longitudinal prospective observational study with a review of literature. Int J Dermatol 2020;59:822–8. in Google Scholar PubMed

46. Anoop, TM, Joseph, PR, Pn, M, Kp, P, Gopan, G, Chacko, S. Cutaneous toxicities in breast cancer patients receiving chemotherapy and targeted agents––an observational clinical study. Clin Breast Cancer 2021;21:434–47. in Google Scholar PubMed

47. Choi, EK, Kim, IR, Chang, O, Kang, D, Nam, SJ, Lee, JE, et al.. Impact of chemotherapy-induced alopecia distress on body image, psychosocial well-being, and depression in breast cancer patients: impact of CIA distress on psychological health in BC patients. Psycho Oncol 2014;23:1103–10. in Google Scholar PubMed

48. Rossi, AM, Hibler, BP, Navarrete-Dechent, C, Lacouture, ME. Restorative oncodermatology: diagnosis and management of dermatologic sequelae from cancer therapies. JAAD 2021;85:693–707. in Google Scholar PubMed PubMed Central

49. Mayer, M, Hunis, A, Oratz, R, Glennon, C, Spicer, P, Caplan, E, et al.. Living with metastatic breast cancer: a global patient survey. Community Oncol 2010;7:406–12. in Google Scholar

50. Hullmann, SE, Robb, SL, Rand, KL. Life goals in patients with cancer: a systematic review of the literature: life goals in patients with cancer. Psycho Oncol 2016;25:387–99. in Google Scholar PubMed PubMed Central

51. Pinquart, M, Fröhlich, C, Silbereisen, RK. Testing models of change in life goals after a cancer diagnosis. J Loss Trauma 2008;13:330–51. in Google Scholar

52. Lampic, C, Thurfjell, E, Bergh, J, Carlsson, M, Sjödén, PO. Life values before versus after a breast cancer diagnosis. Res Nurs Health 2002;25:89–98. in Google Scholar PubMed

53. Institut national du cancer. Démographie médicale en cancérologie – État des lieux. Paris; 2016. Available from: in Google Scholar

Supplementary Material

This article contains supplementary material (

Received: 2022-12-22
Accepted: 2023-02-03
Published Online: 2023-04-03

© 2023 the author(s), published by De Gruyter, Berlin/Boston

This work is licensed under the Creative Commons Attribution 4.0 International License.

Downloaded on 3.3.2024 from
Scroll to top button